Navigation Links
MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE,Molecule

- New Compound Targeting Receptor Tyrosine Kinase EphA2 Shows Tumor Destruction at Low Dose Levels in Preclinical Models -

GAITHERSBURG, Md. and CARLSBAD, Calif., April 19, 2007 /PRNewswire-FirstCall/ -- MedImmune, Inc. and Micromet, Inc. today announced that published proof-of-concept data with a new BiTE(R) molecule (bscEphA2xCD3) show that the compound killed tumor cells at dose levels considerably below those required by classical monoclonal antibody-based therapies. The in vitro and in vivo data, collected from cell culture experiments conducted under the companies' BiTE(R) technology research collaboration, were published in the April 15, 2007 issue of Cancer Research.

BiTE molecules represent a novel class of drugs that function as bi- specific T-cell engagers. They are unique in their ability to enable the body's killer T cells to recognize and attack tumor and target cells, leaving normal cells unharmed. bscEphA2xCD3 is a BiTE molecule targeting the tyrosine kinase receptor EphA2, which is frequently overexpressed on a wide variety of solid tumors.

"The results of this study show that a receptor tyrosine kinase may be an appropriate target for a BiTE molecule," said Patrick Baeuerle, Ph.D., Micromet's Chief Scientific Officer. "This highlights the breadth of the BiTE technology for creating molecules that target different kinds of antigens. Recognition of selected sites on a target antigen may provide a means to widen the therapeutic window for this highly potent therapeutic approach."

In the preclinical study, tumor cell destruction approached 100 percent even at low ratios of effector T cells to target cells. In animal models, the BiTE compound redirected unstimulated human T cells to inhibit outgrowth of transplanted human tumor cells. Time-lapsed videomicroscopy showed that bscEphA2xCD3 triggered T cells to destruct tumor cells overexpressing EphA2, but spared normal cells wher
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. MedImmune Announces Positive Clinical Results at PAS Annual Meeting From Large Prospective Trial in Prevention of Serious RSV Disease
5. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
6. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
7. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
8. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
9. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
10. Micromet, Inc. to Present at the 3rd Annual C.E. Unterberg, Towbin Emerging Growth Conference
11. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: MedImmune and Micromet Publish Data Novel Anti Cancer BiTE Molecule
(Date:9/18/2014)... September 18, 2014 According ... (Surface & Intravascular Systems- Warming & Cooling), Application ... (Surgeon & Anesthesiologist, Nursing & Paramedical Staff) - ... MarketsandMarkets, this report studies the global Temperature Management Market ... The market is expected to reach $2.5 Billion ...
(Date:9/18/2014)... LONDON , Sept. 18, 2014 ... for innovation, increasing clinical development costs, new technologies ... fast-changing environment are important factors driving industry change. ... trial costs continue to rise due to a ... conducted by industry think tanks suggest each day ...
(Date:9/18/2014)... , Sept. 18, 2014  Decision Resources Group ... endothelial growth factor (VEGF) agent for wet AMD, is ... Advantage plans as Genentech,s Lucentis, which is the standard ... managed care organization (MCO) directors do not identify a ... slightly more likely than Lucentis to be listed on ...
Breaking Medicine Technology:Temperature Management Market Worth $2.5 Billion by 2019 2Temperature Management Market Worth $2.5 Billion by 2019 3Temperature Management Market Worth $2.5 Billion by 2019 4Patient Recruitment in Asia Biotech and Pharma Companies 2Patient Recruitment in Asia Biotech and Pharma Companies 3Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 2Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 3
... , NEW BRUNSWICK, N.J., Nov. 12 Senesco ... SNT ) announced today that Catherine Taylor, ... presenting pre-clinical stability and biological activity data on ... 2009 American Association for Cancer Research (AACR)-National Cancer ...
... Thoratec Corporation (Nasdaq: THOR ), a world leader ... and restore failing hearts, said today that it will ... HeartMate II Destination Therapy clinical trial that will be ... the American Heart Association(AHA) Scientific Sessions 2009. , The ...
Cached Medicine Technology:Senesco Presents Pre-Clinical Stability and Biological Activity Data on SNS-01 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 2Senesco Presents Pre-Clinical Stability and Biological Activity Data on SNS-01 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 3
(Date:9/19/2014)... September 19, 2014 VogueQueen.com ... dresses that will make ladies more beautiful at their ... that everyone can afford. The company’s new products are ... providing offering great savings for all the global clients. ... are extremely beautiful. I have ordered several items on ...
(Date:9/18/2014)... 2014 Defendants in more than ... pending in Pennsylvania’s Philadelphia Court of Common Pleas ... behalf of out-of-state plaintiffs dismissed, Bernstein Liebhard LLP ... the defendants maintain that circumstances surrounding the alleged ... have no connection to Pennsylvania. The filings did ...
(Date:9/18/2014)... ON (PRWEB) September 18, 2014 Dr. ... Plastic Surgeon with the American Academy of Facial Plastic ... of Toronto in the Division of Facial Plastic Surgery. ... work in facial plastic surgery. , Dr. Ellis ... foremost, he will be presenting on injection techniques and ...
(Date:9/18/2014)... Exposure to diverse communities may boost infants, social learning, ... languages in the park or supermarket could help children ... are different from them, researchers found. "Research ... against interacting with and learning from people who are ... Chicago psychology professor, said in a university news release. ...
(Date:9/18/2014)... 18, 2014 "Medical staff need better ... also maintaining the patient's privacy," said one of two ... idea in order to supply caregivers with the equipment ... created a prototype for The Helper to make it ... to turn patient onto his or her side. It ...
Breaking Medicine News(10 mins):Health News:VogueQueen.com’s New Line Of Cheap Wedding Dresses Aims To Attract Chic Ladies 2Health News:Xarelto Lawsuit Defendants Seek to Have Pennsylvania Claims Filed by Out-of-State Plaintiffs Dismissed, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Defendants Seek to Have Pennsylvania Claims Filed by Out-of-State Plaintiffs Dismissed, Bernstein Liebhard LLP Reports 3Health News:Dr. David A. F. Ellis Has Been Invited to Speak at a Conference of the American Academy of Facial Plastic and Reconstructive Surgery in Orlando, Florida 2Health News:Study: Exposure to Diversity Might Boost Baby's Social Skills 2
... TSX: COM , VANCOUVER, Nov. 6 /PRNewswire-FirstCall/ - Cardiome ... announced that it will report financial results for the third ... November 9, 2009. Cardiome will hold a teleconference call and ... discuss the results. , To access the conference call, please ...
... The Leukemia & Lymphoma Society (LLS) will again be participating ... two campaigns this past spring and summer, garnered more than $1 ... and support services. , During the campaign, taking place from November ... discount coupons participants can use (in-store only) at all ...
... , WASHINGTON, Nov. 6 The U.S. bishops sent an ... as House members steeped themselves in debate over procedures related ... before meeting to discuss proposed amendments to the bill, the ... of "an amendment to keep in place current federal law ...
... VA)--Three leading scientific organizations specializing in infectious diseases ... expressing their significant concern with current federal guidance ... by healthcare workers in treating suspected or confirmed ... Society for Healthcare Epidemiology of America (SHEA), the ...
... researcher says , FRIDAY, Nov. 6 (HealthDay News) -- New ... within five years of developing the disease are more likely ... others with the condition. , The findings, published Nov. 4 ... who relapse within five years of developing it are nearly ...
... ... Product Lines , ... (PRWEB) November 6, 2009 -- WAV, Inc., the value-added distributor of ... with Vecima Networks Inc. (TSX:VCM), a leading provider of equipment supporting broadband access ...
Cached Medicine News:Health News:Cardiome to Release Third Quarter Results 2Health News:Cardiome to Release Third Quarter Results 3Health News:Get a Jump on Your Holiday Shopping and Give Two Gifts This Season: One to Your Loved Ones and One to People Battling Blood Cancer 2Health News:Bishops to House: Keep Abortion Funding Out of Health Care Reform, Make Health Care Available to Vulnerable 2Health News:Bishops to House: Keep Abortion Funding Out of Health Care Reform, Make Health Care Available to Vulnerable 3Health News:Bishops to House: Keep Abortion Funding Out of Health Care Reform, Make Health Care Available to Vulnerable 4Health News:Bishops to House: Keep Abortion Funding Out of Health Care Reform, Make Health Care Available to Vulnerable 5Health News:Prevention experts urge modification to 2009 H1N1 guidance for health care workers 2Health News:Early Relapse of MS May Mean Fewer Issues Later 2Health News:WAV Distribution Partners with Vecima Networks Inc. 2Health News:WAV Distribution Partners with Vecima Networks Inc. 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: